UNSPSC 51433103: Angiotensinamide

This classification denotes a therapeutic hormone with the molecular formula C49H70N14O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7WAL1X78KV, chemically known as l-phenylalanine, n-(1-(n-(n-(n-(n-(n2-l-asparaginyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-valyl)-l-histidyl)-l-prolyl)- but generally known as angiotensin amide, which bears US NIH Compound Identifier 5890. European Medicines Agency schedules Angiotensinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05511MIG.

UNSPSC 51433103 Angiotensinamide, a Commodity code, represents pharmaceutical products purchased by state and local governments for emergency medical services, pharmacy benefit programs, and healthcare delivery. Recent solicitations show state and local buyers acquiring specific medications—epinephrine injections, labetalol, adenosine, and diltiazem vials among them—for emergency response and pharmacy distribution, often bundled with broader advanced life support or generic pharmaceutical procurement initiatives. Issuing bodies include city fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances serving state agencies and local government facilities. The scope extends from direct municipal emergency-services procurement to statewide pharmacy benefit program administration and cooperative purchasing arrangements spanning multiple jurisdictions.

Activity concentrates in Florida and Texas, with multistate cooperative vehicles like MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) extending reach to Oregon and other participating states. The City of Tampa's Purchasing Department solicited advanced life support medications via IFB (Bid No. 26-P-00188) due April 8, 2026, for Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term plus optional renewals, offering a 5 percent bid discount for Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, establishing contracts effective July 1, 2026, across authorized wholesalers serving state and local government facilities in multiple states. The Texas Health and Human Services Commission posted an exploratory RFI (HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling the state's interest in restructuring pharmacy benefit procurement outside traditional PBM and GPO channels.